Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and gastrointestinal side effects pose challenges for adherence …